Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Other Non-current Assets
Long-term assets not reported separately.
Apogee Therapeutics, Inc.NASDAQ: APGE
Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Other non-current assets rises 19.8% from a year ago
Other non-current assets stood at $10.61M at the end of Q2 FY2026, up 19.8% from a year earlier and down 94.9% from the prior quarter.
Context
- Other non-current assets amounted to 0.8% of total assets at the end of Q2 FY2026, down 0.6 pp from a year earlier.
- Other non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +19.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 181.4M USD
- Year-over-year change
- +36325.9%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 181.4M | +36325.9% |
| FY2024 | 2024-12-31 | 498K | +24.2% |
| FY2023 | 2023-12-31 | 401K | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Assets vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +19.8% is the 5th highest of 9, against a peer median of +8.4%.
- Other non-current assets amounts to 0.8% of total assets for APGE, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $55M USD | -11.8% | -10.2% | 4.2% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥30.74M CNY | -47.9% | -56.0% | 0.8% |
| Sep 2026 | $25.8M USD | +134.8% | +49.8% | 1.5% | |
| Jun 2026 | $10.61M USD | +19.8% | — | 0.8% | |
| Sep 2026 | $9.16M USD | +28.7% | -2.6% | 0.8% | |
| Jun 2026 | $7.54M USD | +38.2% | +47.3% | 0.7% | |
| Sep 2026 | $6.92M USD | +5969.3% | +270.5% | 0.7% | |
| Mar 2026 | $1.28M USD | -32.0% | -8.5% | 0.2% | |
| Jun 2026 | $661K USD | — | +119.1% | 0.1% | |
IRONDisc Medicine, Inc. | Sep 2026 | $496K USD | -34.2% | +84.3% | 0.1% |
| Peer median (excluding APGE) | — | +8.4% | +47.3% | 0.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.